Header

UZH-Logo

Maintenance Infos

High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma : A multicentre study


Compter, I; Zaugg, K; et al (2012). High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma : A multicentre study. Strahlentherapie und Onkologie, 188(10):887-893.

Abstract

Purpose: The goal of the present study was to analyze long-term results of fractionated stereotactic radiotherapy (SRT) in patients with a meningioma.
Methods and materials: A total of 72 patients treated between 1996 and 2008 in MAASTRO clinic (n = 45) and University Hospital Zurich (n = 27) were included. SRT was given as primary treatment (n = 46), postoperatively (n = 19) or at recurrence (n = 7); 49 tumours (68%) were located in the skull base. Median total dose was 54 Gy.
Results: Median follow-up was 4.13 years (range 0.66–11 years). The 3- and 5-year overall survival were 92 and 79% for grade 0 and I meningioma. Progression-free survival for grade 0 and I was 95% at 3 and 5 years, and 40% for grade II and III at 3 years. In 98.4% of patients, clinical symptoms were stable or improved. The majority of symptoms improved within 24 months after SRT. Local control is significantly better if patients are irradiated immediately after diagnosis compared to a watchful waiting policy (p = 0.017). Grade IV toxicity was low (4.2%, n = 3)
Conclusion: SRT is an effective treatment with high local and clinical control. Early SRT resulted in better outcome than late treatment at progression.

Abstract

Purpose: The goal of the present study was to analyze long-term results of fractionated stereotactic radiotherapy (SRT) in patients with a meningioma.
Methods and materials: A total of 72 patients treated between 1996 and 2008 in MAASTRO clinic (n = 45) and University Hospital Zurich (n = 27) were included. SRT was given as primary treatment (n = 46), postoperatively (n = 19) or at recurrence (n = 7); 49 tumours (68%) were located in the skull base. Median total dose was 54 Gy.
Results: Median follow-up was 4.13 years (range 0.66–11 years). The 3- and 5-year overall survival were 92 and 79% for grade 0 and I meningioma. Progression-free survival for grade 0 and I was 95% at 3 and 5 years, and 40% for grade II and III at 3 years. In 98.4% of patients, clinical symptoms were stable or improved. The majority of symptoms improved within 24 months after SRT. Local control is significantly better if patients are irradiated immediately after diagnosis compared to a watchful waiting policy (p = 0.017). Grade IV toxicity was low (4.2%, n = 3)
Conclusion: SRT is an effective treatment with high local and clinical control. Early SRT resulted in better outcome than late treatment at progression.

Statistics

Citations

11 citations in Web of Science®
11 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 18 Oct 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, not refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:18 Oct 2012 09:25
Last Modified:02 Jul 2017 05:04
Publisher:Springer
ISSN:0179-7158
Publisher DOI:https://doi.org/10.1007/s00066-012-0155-7
PubMed ID:22961046

Download

Preview Icon on Download
Content: Published Version
Filetype: PDF - Registered users only
Size: 564kB
View at publisher